150 Followers on Owler

Proteostasis Therapeutics

Proteostasis Therapeutics is engaged in developing small molecule drugs to treat neurodegenerative, genetic and inflammatory disorders. Read more

Meenu Chhabra's photo - President & CEO of Proteostasis Therapeutics

President & CEO

Meenu Chhabra

CEO Approval Rating

64/100

Founded:

2006

Status:

PrivateMerged with Yumanity Therapeutics, Inc.

PROTEOSTASIS THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Proteon has been one of Proteostasis Therapeutics's top competitors. Proteon's headquarters is in Waltham, Massachusetts, and was founded in 2001. Like Proteostasis Therapeutics, Proteon also competes in the Biotechnology field. Proteon generates 4.00% of Proteostasis Therapeutics's revenue.

G1 Therapeutics is one of Proteostasis Therapeutics's top rivals. G1 Therapeutics is a Public company that was founded in Research Triangle Park, North Carolina in 2008. Like Proteostasis Therapeutics, G1 Therapeutics also works within the Biotechnology industry. G1 Therapeutics has 78 more employees vs. Proteostasis Therapeutics.

Fate is perceived as one of Proteostasis Therapeutics's biggest rivals. Fate was founded in 2007, and is headquartered in San Diego, California. Like Proteostasis Therapeutics, Fate also competes in the Biotechnology sector. Fate generates $35.1M more revenue vs. Proteostasis Therapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $5M a good estimate for Proteostasis Therapeutics's revenue?

Proteostasis Therapeutics Acquisitions

No recent acquisitions found related to Proteostasis Therapeutics

Proteostasis Therapeutics Funding History

Since Proteostasis Therapeutics was founded in 2006, it has participated in 4 rounds of funding. In total Proteostasis Therapeutics has raised $162.6M. Proteostasis Therapeutics' last funding round was on Feb 2016 for a total of $50.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Feb 2016
$50M

Series B
Sep 2015
$37M
Debt
Jul 2014
$5M
Series A
Aug 2008
$70.6M

Since Proteostasis Therapeutics was founded in 2006, it has participated in 4 rounds of funding. In total Proteostasis Therapeutics has raised $162.6M. Proteostasis Therapeutics' last funding round was on Feb 2016 for a total of $50.0M

Proteostasis Therapeutics Investments

No recent investments found related to Proteostasis Therapeutics

Proteostasis Therapeutics News

November 16, 2020St Louis Post Dispatch

3Q Earnings Snapshot

BOSTON (AP) - Proteostasis Therapeutics Inc. (PTI) on Monday reported a loss of $8.2 million in its t... See more »
November 16, 2020BioSpace

Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results

- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today ann... See more »
October 17, 2020Micro Small Cap

Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - GLIBA, PTI, MR, CBMG

NEW YORK, NY / ACCESSWIRE / October 17, 2020 / Halper Sadeh LLP, a global investor rights law firm, i... See more »
October 6, 2020MarketScreener

WeissLaw LLP Reminds PTI and NETE Shareholders About Its Ongoing Investigations

(marketscreener.com) NEW YORK, Oct. 5, 2020 /PRNewswire/ -- If you own shares in any of the companies... See more »
September 22, 2020Micro Small Cap

Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm - PTI, BYFC, RST, AIMT

NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Halper Sadeh LLP, a global investor rights law firm,... See more »
September 9, 2020Pharamceutical Technology

Yumanity and Proteostasis merger

Two Boston-based companies, Yumanity Therapeutics and Proteostasis Therapeutics, have signed a merger... See more »
August 28, 2020MarketScreener

Monteverde & Associates PC Announces an Investigation of Proteostasis Therapeutics, Inc. - PTI

(marketscreener.com) NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing pa... See more »

Proteostasis Therapeutics Press Releases

May 13, 2020centralcharts

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Confer... See more »
February 24, 2020PR Newswire

Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis

BOSTON, Feb. 24, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage ... See more »
January 22, 2020PR Newswire

Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients

BOSTON, Jan. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage ... See more »
December 17, 2019centralcharts

Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients

Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator ... See more »
December 2, 2019PR Newswire

Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage b... See more »
November 27, 2019centralcharts

Proteostasis Therapeutics, Inc. - PTI Stock Chart Technical Analysis for 11-27-2019

News videos - Proteostasis Therapeutics, Inc. - PTI Stock Chart Technical Analysis for 11-27-2019 - P... See more »
November 7, 2019PR Newswire

Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

BOSTON, Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage b... See more »

Social Media

Proteostasis Therapeutics Headquarters

40 Guest Street Suite 4410

Boston, Massachusetts02135

617-409-5300

Driving Directions »

Trending Companies

Proteostasis Therapeutics Summary

ABOUT

Overview

Proteostasis Therapeutics is engaged in developing small molecule drugs to treat neurodegenerative, genetic and inflammatory disorders. Proteostasis Therapeutics was founded in 2006. Proteostasis Therapeutics' headquarters is located in Boston, Massac...

CEO

Proteostasis Therapeutics's President & CEO, Meenu Chhabra, currently has an approval rating of 64%. Proteostasis Therapeutics's primary competitors are Proteon, G1 Therapeutics & Fate.

Frequently Asked Questions about Proteostasis Therapeutics

  1. When was Proteostasis Therapeutics founded?

    Proteostasis Therapeutics was founded in 2006
  2. Who is Proteostasis Therapeutics's CEO?

    Proteostasis Therapeutics's CEO is Meenu Chhabra
  3. How much revenue does Proteostasis Therapeutics generate?

    Proteostasis Therapeutics generates $5M in revenue
  4. How much funding does Proteostasis Therapeutics have?

    Proteostasis Therapeutics has historically raised $162.6M in funding
  1. Where is Proteostasis Therapeutics's headquarters?

    Proteostasis Therapeutics's headquarters is in Boston Massachusetts, USA
  2. How many employees does Proteostasis Therapeutics have?

    Proteostasis Therapeutics has 44 employees
  3. What sector does Proteostasis Therapeutics operate in?

    Proteostasis Therapeutics is in Biotechnology
  4. Who are Proteostasis Therapeutics's competitors?

    Proteostasis Therapeutics's top competitors are Proteon, G1 Therapeutics, Fate